On September 18, 2014, Purdue Pharmaceuticals released results from two studies evaluating the reformulated version of OxyContin®, which was re-introduced back into the marketplace in 2010. If you recall, OxyContin was reformulated to deter abuse, misuse, and diversion by making the tablet impossible to crush and thereby making it difficult to snort or inject.
OxyContin® is FDA indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
A synopsis of the study results can be found at the below link. The study has shown that rates of both abuse and diversion have declined significantly since 2010 and continues to decline since the re-introduction of the new formulation.
Being that OxyContin® is a common long-acting opioid routinely found on the claims payment history of workers’ compensation patients, these results can only be encouraging.